Biological therapy of B and T cell lymphoproliferative disorders

  • Robert O. Dillman

Biotherapy has consistently exhibited significant activity in lymphoid malignancies. The first report of a complete remission with a monoclonal antibody in 1982 was in a patient with follicular lymphoma. Interferon alpha (IFN-α) became the first biological approved for the treatment of malignancy in 1986, because of its activity in hairy cell leukemia, and for many years was used in the treatment of lymphoma. The first monoclonal antibody approved for the treatment of a malignancy was the anti-CD20 chimeric Mab rituximab, which has become a block-bluster drug since its approval in 1997. The first immunotoxin to gain regulatory approval, denileukin diftitox was approved based on activity in T cell lym-phoma. The anti-CD52 humanized Mab alemtuzumab was approved based on its activity in CLL. The first two radiolabeled antibodies approved for cancer treatment were the anti-CD20 products Y-90 ibritumomab tiuxetan and I-131 tositumomab which are very active in the treatment of B cell lymphoma. Finally, it is widely anticipated that perhaps one or more of the patient-specific vaccines consisting of idiotype protein may become the first tumor specific vaccines to receive regulatory approval as treatment for follicular lymphoma.


Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Hairy Cell Leukemia Indolent Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Allison MA, Jones SE, McGuffey P. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. J Clin Oncol 1989;7:75–80.PubMedGoogle Scholar
  2. 2.
    Aviles A, Guzman R, Garcia EL, Maqueo JC. Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma. Cancer Biother Radiopharm 1996;11:21–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Aviles A, Leon MI, Diaz-Maqueo JC, et al. Rituximab in the treatment of refractory follicular lymphoma–six doses are better than four. J Hematother Stem Cell Res 2001;10:313–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Aviles A, Neri N, Huerta-Guzman J, et al. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma. Leuk Lymphoma. 2004;4:2247–51.CrossRefGoogle Scholar
  5. 5.
    Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immu-nologic findings in 14 patients. Haematologica 2007;92:784–94.PubMedCrossRefGoogle Scholar
  6. 6.
    Bernstein Z P, Vaickus L, Friedman N, et al. Interleukin-2 lym-phokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991;10:141–146.PubMedCrossRefGoogle Scholar
  7. 7.
    Boussiotis VA, Pangalis GA. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up. Br J Haematol 1991;79 Suppl 1:30–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Bremer K. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. Anticancer Drugs 2003;14:809–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Breneman D, Duvic M, Kuzel T et al. Phase 1 and 2 trial of bexaro-tene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Bunn PA, Jr., Ihde DC, Foon KA. The role of recombinant inter-feron alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986;57:1689–1695.PubMedCrossRefGoogle Scholar
  11. 11.
    Buske C, Dreyling MH, Eimermacher H et al. Combined immuno-chemotherapy (R-CHOP) results in superior response rates and time to treatment failure in first line of patients with lymphoplas-macytoid/immunocytoma. Blood 2004;104:50a [abstract 162].Google Scholar
  12. 12.
    Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–64.PubMedGoogle Scholar
  13. 13.
    Byrd JC, Peterson B, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6–14.PubMedCrossRefGoogle Scholar
  14. 14.
    Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Case DC Jr, Ebrahim K, Hedlund J, et al. Rituxiab in relapsed fol-licular lymphoma. Blood 2002;100:292b [abstract #4704].Google Scholar
  16. 16.
    Cheng AL, Su IJ, Chen CC, et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol 1994;12:1185–1192.PubMedGoogle Scholar
  17. 17.
    Cheson BD, Sorenson JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–15.PubMedGoogle Scholar
  18. 18.
    Chiarion-Sileni V, Bononi A, Fornasa CV et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002;95:569–75.PubMedCrossRefGoogle Scholar
  19. 19.
    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.PubMedGoogle Scholar
  20. 20.
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42.PubMedCrossRefGoogle Scholar
  21. 21.
    Colombat P, Salles G. Brousse, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with folli-cular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101–6.Google Scholar
  22. 22.
    Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Cortelezzi A, Pasquini MC, Sarina B, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005;90:410–2.PubMedGoogle Scholar
  24. 24.
    Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileu-kin diftitox for relapsed/refractory B-Cell non-Hodgkin's lym-phoma. J Clin Oncol 2004;22:4095–102.PubMedCrossRefGoogle Scholar
  25. 25.
    Dang NH, Fayad L, McLaughlin P, et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 2007;138:502–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileu-kin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007;136:439–47.PubMedCrossRefGoogle Scholar
  27. 27.
    Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1469–79.PubMedCrossRefGoogle Scholar
  28. 28.
    Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611–5.PubMedGoogle Scholar
  29. 29.
    Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–43.PubMedGoogle Scholar
  30. 30.
    Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Davis T, White CA, Grillo-Lopez A, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851–1857.PubMedGoogle Scholar
  32. 32.
    Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002;20:3545–57.PubMedCrossRefGoogle Scholar
  33. 33.
    Dillman RO, Shawler DL, Sobol RE, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 1982;59:1036–45.PubMedGoogle Scholar
  34. 34.
    Dillman RO, Shawler DL, Dillman JB, et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 1984;2:881–91.PubMedGoogle Scholar
  35. 35.
    Dillman RO, Beauregard J, Shawler DL et al. Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Response Mod 1986;5:394–410.PubMedGoogle Scholar
  36. 36.
    Dillman RO, Schreeder MT, Hon JK, et al. Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother Radiopharm 2007;22:185–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Drapkin R, Di Bella NJ, Cuasay LC, et al. Phase II multicenter trial of pentostatin and rituximab in patients with previously treated or untreated chronic lymphocytic leukemia. Blood 2002;100:803a [abstract 3171].Google Scholar
  39. 39.
    Dreno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991;125:456–459.PubMedCrossRefGoogle Scholar
  40. 40.
    Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Duggan DB, Santarelli MT, Zamkoff K, et al. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B. J Immunother 1992;12:115–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lym-phoma: multinational phase II–III trial results. J Clin Oncol 2001a;19:2456–71.Google Scholar
  43. 43.
    Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001b;137:581–93.Google Scholar
  44. 44.
    Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Englad G, Hagberg H, Erlanson M, et al. A pilot study of alemtu-zumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–4.CrossRefGoogle Scholar
  46. 46.
    Ferrara F, Rametta V, Mele G, et al. Recombinant interferon-alpha 2A as maintenance treatment for patients with advanced stage chronic lymphocytic leukemia responding to chemotherapy. Am J Hematol 1992;41:45–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Feugier P, Va n Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'. Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006;107:2408–16.PubMedCrossRefGoogle Scholar
  49. 49.
    Fisher RI, Dana BW, LeBlanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000;18:2010–6.PubMedGoogle Scholar
  50. 50.
    Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565–7573.PubMedCrossRefGoogle Scholar
  51. 51.
    Flowers CR. BiovaxID idiotype vaccination: active immunother-apy for follicular lymphoma. Expert Rev Vaccines 2007;6:307–17.PubMedCrossRefGoogle Scholar
  52. 52.
    Foon KA, Bunn PA Jr. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia. Semin Oncol 1986;13(4 Suppl 5):35–9.Google Scholar
  53. 53.
    Foon KA, Schroff RW, Bunn PA, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984;64:1085–1093.PubMedGoogle Scholar
  54. 54.
    Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317–24.PubMedGoogle Scholar
  55. 55.
    Forstpointner R, Dreyling M, Repp R, et al. The addition of ritux-imab to a combination of fludarabine, cyclophosphamide, mitox-antrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–71.PubMedCrossRefGoogle Scholar
  56. 56.
    Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106:454–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Foss FM, Ihde DC, Breneman DL, et al. Phase II study of pentosta-tin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1992;10:1907–13.PubMedGoogle Scholar
  59. 59.
    Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/ Sézary syndrome. J Clin Oncol 1994;12:2051–9.PubMedGoogle Scholar
  60. 60.
    Foss FM, Raubitscheck A, Mulshine JL, et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 1998;4:2691–700.PubMedGoogle Scholar
  61. 61.
    Friedberg JW, Neuberg D, Gribben JG, et al. Combination immu-notherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117:828–34.PubMedCrossRefGoogle Scholar
  62. 62.
    Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316–23.PubMedCrossRefGoogle Scholar
  63. 63.
    Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–55.PubMedCrossRefGoogle Scholar
  64. 64.
    Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004;103:4416–23.PubMedCrossRefGoogle Scholar
  65. 65.
    Gisselbrecht C, Maraninchi D, Pico JL, et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994;83:2081–5.PubMedGoogle Scholar
  66. 66.
    Golomb HM, Ratain MJ, Fefer A, et al. Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 1988;80:369–73.PubMedCrossRefGoogle Scholar
  67. 67.
    Golomb HM, Dodge R, Mick R, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recom-binant alpha-interferon: a report of CALGB study 8515. Leukemia 1994;8:2037–40.PubMedGoogle Scholar
  68. 68.
    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lym-phoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998;16:41–47.PubMedGoogle Scholar
  70. 70.
    Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088–95.PubMedCrossRefGoogle Scholar
  71. 71.
    Herold M, Hass A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986–92.PubMedCrossRefGoogle Scholar
  72. 72.
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxo-rubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–32.PubMedCrossRefGoogle Scholar
  73. 73.
    Huhn D, von Schilling C, Wilhelm M, et al Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326–31.PubMedCrossRefGoogle Scholar
  74. 74.
    Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical ben-efit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006;98:1292–301.PubMedCrossRefGoogle Scholar
  75. 75.
    Golomb HM, Jacobs A, Fefer A et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986;4:900–5.PubMedGoogle Scholar
  76. 76.
    Gordon LI, Witzig T, Molina A et al. Yttrium 90-labeled ibritu-momab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004;5:98–101.PubMedCrossRefGoogle Scholar
  77. 77.
    Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974–82.PubMedGoogle Scholar
  78. 78.
    Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodg-kin's lymphoma. J Clin Oncol 2002;20:4261–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746–51.PubMedCrossRefGoogle Scholar
  80. 80.
    Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–23.PubMedCrossRefGoogle Scholar
  81. 81.
    Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1989;7:1533–38.PubMedGoogle Scholar
  82. 82.
    Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositu-momab and iodine-131 tositumomab (Bexxar) in B-cell lym-phoma, progressive after rituximab. J Clin Oncol 2005;23:712–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 1997;89:3129–35.PubMedGoogle Scholar
  84. 84.
    Huang CL, Lin ZZ, Su IJ, et al. Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma. Leuk Lymphoma 2002;43:1415–20.PubMedGoogle Scholar
  85. 85.
    Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001;73:213–21.PubMedCrossRefGoogle Scholar
  86. 86.
    Jacobs AD, Champlin RE, Golde DW. Recombinant alpha-2-inter-feron for hairy cell leukemia. Blood 1985;65:1017–20.PubMedGoogle Scholar
  87. 87.
    Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974–81.PubMedGoogle Scholar
  88. 88.
    Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of Iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell lymphomas. J Clin Oncol 2001;19:3918–28.PubMedGoogle Scholar
  90. 90.
    Kay NE, Geyer SM, Call TG, et al. Combination chemotherapy with pentostatin, cyclophosphamide, and rituximab shows significant activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.PubMedCrossRefGoogle Scholar
  91. 91.
    Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–61.PubMedCrossRefGoogle Scholar
  92. 92.
    Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–88.PubMedCrossRefGoogle Scholar
  93. 93.
    Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003;71:250–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201–204.PubMedCrossRefGoogle Scholar
  95. 95.
    Khan KD, Emmanouilides C, Benson DM Jr, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:7046–53.PubMedCrossRefGoogle Scholar
  96. 96.
    Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as frontline chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129–34.PubMedCrossRefGoogle Scholar
  97. 97.
    Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996;87:893–899.PubMedGoogle Scholar
  98. 98.
    Kuzel TM, Roenig HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fun-goides and the Sézary syndrome. J Clin Oncol 1995;13:257–63.PubMedGoogle Scholar
  99. 99.
    Kuzel TM, Li S, Eklund J, et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma 2007;48:2397–402.PubMedCrossRefGoogle Scholar
  100. 100.
    Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209–15.PubMedCrossRefGoogle Scholar
  101. 101.
    Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophos-phamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575.PubMedCrossRefGoogle Scholar
  102. 102.
    Langenmayer I, Nerl C, Knauf W, et al. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study. Br J Haematol 1996;94:362–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001;86:1046–50.PubMedGoogle Scholar
  104. 104.
    LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998;91:399–405.PubMedGoogle Scholar
  105. 105.
    Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemo-therapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lym-phoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104:2667–74.PubMedCrossRefGoogle Scholar
  106. 106.
    Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–92.PubMedCrossRefGoogle Scholar
  107. 107.
    Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696–704.PubMedCrossRefGoogle Scholar
  108. 108.
    Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257–3263.PubMedGoogle Scholar
  109. 109.
    Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–73.PubMedCrossRefGoogle Scholar
  110. 110.
    Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtu-zumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267–72.PubMedCrossRefGoogle Scholar
  111. 111.
    Maier T, Tun-Kyi A, Tassis A, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autolo-gous tumor-lysate-pulsed dendritic cells. Blood 2003;102:2338–44.PubMedCrossRefGoogle Scholar
  112. 112.
    Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus ritux-imab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–23.PubMedCrossRefGoogle Scholar
  113. 113.
    Margolin KA, Aronson FR, Sznol M, et al. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother 1991;10:214–220.PubMedCrossRefGoogle Scholar
  114. 114.
    Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of ritux-imab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979–83.PubMedCrossRefGoogle Scholar
  115. 115.
    Mauro FR, Zinzani P, Zaja F et al. Fludarabine + prednisone +/-alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lympho-cytic leukemia: long term results of a randomized study. Haematologica 2003;88:1348–57.PubMedGoogle Scholar
  116. 116.
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chi-meric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–33.PubMedGoogle Scholar
  117. 117.
    McLaughlin P, Hagemeister FB, Romaguera J, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemtotherapy (fludarabine, mitoxantrone, dex-amethasone) and rituximab monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol 2003;22:564 [abstract 2269]Google Scholar
  118. 118.
    McSweeney EN, Giles FJ, Worman CP, et al. Recombinant inter-feron alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 1993;85:77–83.PubMedCrossRefGoogle Scholar
  119. 119.
    Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790–5.PubMedGoogle Scholar
  120. 120.
    Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987;67:232–6.PubMedGoogle Scholar
  121. 121.
    Mones JV, Coleman M, Kostakoglu L, et al. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositu-momab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma 2007;48:342–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337–42.PubMedCrossRefGoogle Scholar
  123. 123.
    Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autolo-gous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896–902.PubMedCrossRefGoogle Scholar
  125. 125.
    Neri N, Aviles A, Cleto S, et al. Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lym-phoma. J Hematother Stem Cell Res 2001;10:669–674.PubMedCrossRefGoogle Scholar
  126. 126.
    Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810–3.PubMedCrossRefGoogle Scholar
  127. 127.
    O'Brien S, Kantarjian H, Beran M, et al. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 1995;86:1298–300.PubMedGoogle Scholar
  128. 128.
    O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–70.PubMedGoogle Scholar
  129. 129.
    O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657–63.PubMedCrossRefGoogle Scholar
  130. 130.
    Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376–88.PubMedGoogle Scholar
  131. 131.
    Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:395–407.PubMedCrossRefGoogle Scholar
  132. 132.
    Osterborg A, Dyer MJS, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously untreated chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567–74.PubMedGoogle Scholar
  133. 133.
    Peterson B, Petroni G, Oken M. Cyclophosphamide + interferon alpha-2b in follicular low-grade lymphomas: a preliminary report on an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 1993;12:1240 (abstract).Google Scholar
  134. 134.
    Pfreundschuh H, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–16.PubMedCrossRefGoogle Scholar
  135. 135.
    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lym-phoma: a randomised controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol 2006;7:379–91.PubMedCrossRefGoogle Scholar
  136. 136.
    Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14 Suppl 1:121–5.PubMedGoogle Scholar
  137. 137.
    Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade or follicular non-Hodgkins lymphoma. Ann Oncol 1999;10:655–61.PubMedCrossRefGoogle Scholar
  138. 138.
    Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositu-momab for previously untreated follicular non-Hodgkin's lym-phoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Prince HM, McCormack C, Ryan G, et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lym-phoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 2001;42:91–7.PubMedCrossRefGoogle Scholar
  140. 140.
    Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol 2004;51:25–32.PubMedCrossRefGoogle Scholar
  141. 141.
    Rai K, Davey F, Peterson B, et al. Recombinant alpha-2b-inter-feron in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia 1995;9:1116–20.PubMedGoogle Scholar
  142. 142.
    Rai K, Mercier RJ, Cooper MR, et al. Campath-1H is an effective salvage therapy for fludarabine failing CLL patients: results of a phase II trial. Blood 2001;96:163a [abstract 703].Google Scholar
  143. 143.
    Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891–7.PubMedCrossRefGoogle Scholar
  144. 144.
    Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idio-type vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol 2006;24:3107–12.PubMedCrossRefGoogle Scholar
  145. 145.
    Reinis M. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma. Curr Opin Mol Ther 2007;9:291–8.PubMedGoogle Scholar
  146. 146.
    Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome. Clin Lymphoma Myeloma 2006;7:226–32.PubMedCrossRefGoogle Scholar
  147. 147.
    Ritchie D, Hermans I, Yang J, et al. Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk Lymphoma 2006;47:675–82.PubMedCrossRefGoogle Scholar
  148. 148.
    Robak T, Smolewski P, Cebula B, et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542–50.PubMedCrossRefGoogle Scholar
  149. 149.
    Rodgriquez-Calvillo M, Inoges S, Lopez-Diaz de Cerio A, et al. Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit Rev Oncol Hematol 2004;52:1–7.Google Scholar
  150. 150.
    Rohatiner A, Radford J, Deakin D, et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001;85:29–35.PubMedCrossRefGoogle Scholar
  151. 151.
    Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215–23.PubMedCrossRefGoogle Scholar
  152. 152.
    Rupoli S, Barulli S, Guiducci B, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica 1999;84:809–13.PubMedGoogle Scholar
  153. 153.
    Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39:63–73.PubMedCrossRefGoogle Scholar
  154. 154.
    Shulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115–20.CrossRefGoogle Scholar
  155. 155.
    Smalley RV, Connors J, Tuttle RL, et al. Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol 1992a;41:13–8.Google Scholar
  156. 156.
    Smalley RV, Andersen JW, Hawkins MJ, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992b;327:1336–1341.CrossRefGoogle Scholar
  157. 157.
    Smalley RV, Weller E, Hawkins MJ, et al. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lym-phoma treated with interferon alfa (IFN-alpha2a) plus an anthracy-cline-based induction regimen. Leukemia 2001;15:1118–1122.PubMedCrossRefGoogle Scholar
  158. 158.
    Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant inter-feron alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993;329:1608–1614.PubMedCrossRefGoogle Scholar
  159. 159.
    Stadler R, Otte HG, Luger T, et al. Prospective randomized mul-ticenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578–81.PubMedGoogle Scholar
  160. 160.
    Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109:1799–803.PubMedCrossRefGoogle Scholar
  161. 161.
    Thestrup-Pedersen K, Hammer R, Kaltoft K, et al. Treatment of mycosis fungoides with recombinant interferon-alpha 2a alone and in combination with etretinate. Br J Dermatol 1988;118:811–8.PubMedCrossRefGoogle Scholar
  162. 162.
    Thomas DA, O'Brien S, Giles FJ, et al. Single agent Rituxan in early stage chronic lymphocytoic leukemia. Blood 2001;98:364a [abstract 1533].Google Scholar
  163. 163.
    Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906–11.PubMedCrossRefGoogle Scholar
  164. 164.
    Thompson JA, Fefer A. Interferon in the treatment of hairy cell leukemia. Cancer 1987;59(3 Suppl):605–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004;15:821–30.PubMedCrossRefGoogle Scholar
  166. 166.
    Treon SP, Agus DB, Link B, et al. CD-20 directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglob-ulinemia. J Immunother 2001;24:272–279.CrossRefGoogle Scholar
  167. 167.
    Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005;16:132–8.PubMedCrossRefGoogle Scholar
  168. 168.
    Unterhalt M, Herrmann R, Tiemann M, et al. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, predni-sone (COP) for the treatment of advanced low-grade non-Hodg-kin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 1996;10:836–43.PubMedGoogle Scholar
  169. 169.
    Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without ritux-imab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–301.PubMedCrossRefGoogle Scholar
  170. 170.
    Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461–7.PubMedCrossRefGoogle Scholar
  171. 171.
    Vose JM, Bierman PJ, Loberiza FR Jr, et al. Phase I trial of (90) Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007;48:683–90.PubMedCrossRefGoogle Scholar
  172. 172.
    Weber JS, Yang JC, Topalian SL, et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992;10:33–40.PubMedGoogle Scholar
  173. 173.
    Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission — experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093–101.PubMedCrossRefGoogle Scholar
  174. 174.
    Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070–8.PubMedCrossRefGoogle Scholar
  175. 175.
    Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiux-etan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005;20:185–8.PubMedCrossRefGoogle Scholar
  176. 176.
    Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 + B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793–803.PubMedGoogle Scholar
  177. 177.
    Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritu-momab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002a;20:3262–9.CrossRefGoogle Scholar
  178. 178.
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radio-immunotherapy versus rituximab immuno- therapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002b;20:2453–63.CrossRefGoogle Scholar
  179. 179.
    Witzig TE, Vukov AM, Habermannn TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:1103–8.PubMedCrossRefGoogle Scholar
  180. 180.
    Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lym-phoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804–10.PubMedCrossRefGoogle Scholar
  181. 181.
    Wollina U, Looks A, Meyer J, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001;44:253–60.PubMedCrossRefGoogle Scholar
  182. 182.
    Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702–3.PubMedGoogle Scholar
  183. 183.
    Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritu-momab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008;112:856–62.PubMedCrossRefGoogle Scholar
  184. 184.
    Kunkel LA. Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma. Cancer Invest 2004;22:97–105.PubMedCrossRefGoogle Scholar
  185. 185.
    Canellos GP. Interferon in the treatment of malignant lymphoma. Semin Oncol 1985;12(4 Suppl 5):25–9.PubMedGoogle Scholar
  186. 186.
    Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253–64.PubMedCrossRefGoogle Scholar
  187. 187.
    Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lympho-cytic leukemia. J Clin Oncol 2007;25:5616–23.PubMedCrossRefGoogle Scholar
  188. 188.
    Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69:129–34.PubMedCrossRefGoogle Scholar
  189. 189.
    Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 2005a;19:1207–10.CrossRefGoogle Scholar
  190. 190.
    O'Connell MJ, Colgan J P, Oken MM et al. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lympho-cytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1986;4:128–36.PubMedGoogle Scholar
  191. 191.
    Peterson BA, Petroni GR, Oken MM, et al. Proc Am Soc Clin Oncol 1997;16:14a (abstract.)Google Scholar
  192. 192.
    Sherwin SA, Knost JA, Fein S et al. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982;248:2461–6.PubMedCrossRefGoogle Scholar
  193. 193.
    Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Robert O. Dillman
    • 1
  1. 1.Hoag Cancer CenterNewport BeachUSA

Personalised recommendations